65,437 trials
Healthy
Primary: AUC(0-t) — 9708; 9696; 9431 ng.h/mL
Breast Cancer
Primary: Drainage Volume — 182.6; 525.2 milliliters — p=<0.05
Hypercholesterolemia
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity) — 168.1355; 176.1731 ng*hr/mL
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at 6 Weeks — -19.44; -18.09; -20.00; -20.57 Units on a Scale — p=0.0041
Dermatitis · Eczema
Primary: Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score). — 131; 134; 37; 38 Participants
Hypercholesterolemia
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity) — 18.3206; 19.2583 ng•hr/mL
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 8,545.50; 9,456.66 ng/mL
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in Choice Reaction Time (CRT) at 6 Weeks — 20.7; 21.9 msec — p=0.844
Infections, Fungal
Primary: Plasma Concentrations of Voriconazole — 839.50; 2182.33 ng/mL
Allergic Rhinitis · Chronic Urticaria
Primary: Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR) — -7.6; -4.0 beats per minute
Infections, Rotavirus
Primary: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains — 0; 13 subjects
Healthy
Primary: Maximum Plasma Concentration (Cmax) — 9,806.74; 9,854.39; 7,950.75; 12,061.67 ng/mL
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Efavirenz — 2,461.58; 2,384.79 ng/mL
Major Depressive Disorder · Insomnia
Primary: Remission of Depression (%) — 61.5; 33.3 percent of participants — p=.13
Hepatitis B
Primary: Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy — 323; 305 Participants — p=<0.001